Investment IdeasMy Portfolio
All Investment Ideas
$4 mln$33 mln$43 mln$143 mln

IPO Forma Therapeutics

Treatment of hematologic diseases and cancers
High risk

Funding history

Invest in IPO Forma Therapeutics

This investment idea is no longer available. New applications are not accepted

View more ideas
Investment Idea Details
The Company

Forma Therapeutics (FMTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers.

FORMA builds on the vision of its academic founders: Stuart Schreiber, Todd Golub and Michael Foley, each of the Broad Institute of Harvard and MIT. FORMA leverages its innovative drug discovery platform to address challenging targets and develop a robust internal pipeline of breakthrough oncology drugs.

Market Opportunity

SCD is the most common type of hemoglobinopathy, a diverse range of rare inherited genetic disorders that affect hemoglobin, the iron-containing protein in RBCs responsible for transporting oxygen in the blood.

According to a 2018 market research report by Grand View Research, the market for sickle cell disease treatment is expected to reach $5.5 billion by 2023, growing at 14% annually.


The company has never generated revenue from product sales and may never be profitable.

This is a biotech company without an approved product. The overall risk is high.


FMTX intends to raise $210 million from an IPO of its common stock at about $700M valuation. The company has entered into partnership agreements with a number of large biotechnological companies (Celgene, Boehringer Ingelheim), which is a positive signal for investors.

Over the past 6 months biotech IPOs have shown high returns of about 50%. The most recent offerings were Pliant Therapeutics (+38%), ADC Therapeutics (+93%).

How IPO Investments Work
1. Collection of funds

2-3 weeks before the start of the company publishes information about the opening of trading: financial statements for 3 years, a description of the company's business, plans for the future, as well as the risks that management sees in their own business. We analyze such offers and publish the best ones. Investors apply for deposits. Before the deadline for applications, you can change the request or cancel it.

16 Jun
Threshold amount
2. Buy shares

We submit one large application for the purchase of shares by pre-subscription with reduced price to large investors. The application may be rejected in part or in full. Over the past three years, our applications have been rejected only three times. The next day, or every other day, we'll know at what price and at what percentage the order is executed, and we'll post it on «The my investment page».

Submit applications before
17 Jun
3. Start Bidding

The price of shares is rising from the first day due to the demand of investors deprived of the opportunity to buy shares before trading. Most of the stocks we've been recommending buying over the past three years have been starting to trade on the stock exchange at tens of percent higher than the price at which customers bought the shares. There comes a Lock up period when it is forbidden to sell shares purchased by subscription. Typically lasts 3 months.

Start Bidding
19 Jun
Return forecast
4. Receiving profit

After the expiration of the Lock Up period, the investment is automatically closed and the investor receives a profit on account of the deduction commissions UT. You can always view the results of your past investments in investment archive.

22 Sep
Early profit fixation

Although no shares are allowed to be sold during the lock-up period, our traders seek to offer investors fixed profit by way of using various financial instruments, including forwards, options, short positions etc.

From the investor’s point of view this means that he or she may close an investment by paying a certain part of its value (as a rule, approximately 15 percent). This is due to high prices for the instruments which are employed to ensure availability of fixed profit. As such, you shall press any relevant button in the Investor Account as soon as it is active.

The closing procedure is similar to commencement of investment business. You shall file a bid which is executed within a business day by UT. So, your investment is closed at the price currently prevailing on the stock exchange. However, we rarely recommend using this feature, since upon expiry of an applicable lock-up period the average performance is higher.



3 per cent of the share price. This fee is charged as soon as your investment bid is confirmed.


1.75 per cent of the purchase price paid for your shares as soon as trading is closed. This fee is charged upon closure of any relevant investment.


20 per cent of the profit your derive. This fee is charged only if you show positive performance as of the moment any relevant investment is closed.


Usually, 15 per cent (depends on the stock exchange environment). It is calculated per each investment individually.

Advantages Enjoyed by Those Investing with United Traders


Our risk managers ensure proper support throughout the entire transaction. Moreover, you may call them on +7 495 646-15-57 or 8 800 333-66-81 or visit our office, if a more detailed discussion is needed.


Such an approach allows it to limit extra risks related to bankruptcy of start-ups and considerably increase profit vs investors purchasing shares on open Market.


Millions of dollars are required to buy shares on a subscription basis. We have generated a pool of traders and investors which enables any newbie to participate in any transaction as aforesaid by investing just USD50 or more.

Invest in IPO Forma Therapeutics

This investment idea is no longer available. New applications are not accepted

View more ideas